Biogen Inc (BIIB)
Mexican Exchange · Mexico · prices in MXN · close of 15 Oct 2026
Key indicators
| Last close | MXN 3,900.80 |
|---|---|
| 52-week range | 2,696.00 – 3,900.80 |
| Return, 1 month / 3 months | +3.3% / +6.7% |
| Return, 1 year / 3 years | +43.4% / −12.3% |
| Trend | Uptrend |
| RSI (14) | 96 |
| Volatility (1 year) | 23.9% |
| Worst drawdown (1 year) | -11.5% |
| Average daily value traded | 0.00M MXN |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Biogen Inc is a biotechnology company based in Cambridge, Massachusetts, that discovers, develops and markets medicines for serious neurological and neurodegenerative conditions. Its products treat multiple sclerosis, spinal muscular atrophy and Alzheimer's disease, and it also offers biosimilar medicines. Its customers are mainly hospitals, specialist physicians and healthcare providers who prescribe these therapies to patients, and it operates research and manufacturing facilities in the United States and internationally.
On this site Biogen Inc appears as a stock on the Mexican Exchange (Mexico), code BIIB, with prices in Mexican pesos (MXN). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Biogen Inc (BIIB) trades on the Mexican Exchange in Mexico. It last closed at MXN 3,900.80 on 15 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 40 of 361 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 43.4% and over the last three months it rose 6.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Mexican Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 82 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 13.4% | ||
| From 52-week high | 0.0% | ||
| Momentum | 78 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 6.7% | ||
| 6-month return | 31.0% | ||
| 12-month return, skipping the last month | 38.9% | ||
| Stability (higher is calmer) | 77 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 23.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -11.5% | ||
| Liquidity | 9 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M MXN | ||
| Zero-volume days | 95.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +3.3% |
| 3 months | +6.7% |
| 6 months | +31.0% |
| 1 year | +43.4% |
| 3 years | −12.3% |
| 5 years | −31.6% |
Signals
| 50-day / 200-day average | 3,784.21 / 3,438.66 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.59 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Mexican Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.